Shukra Pharmaceuticals Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: SHUKRAPHAR BSE: 524632
₹62.09
▲ 1.79 (2.97%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
69/100
Moderate
Valuation
—/100
Expensive
Momentum
79/100
Bullish

QVM read Momentum-led Quality Moderate, Valuation Expensive, Momentum Bullish

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹2,719 Cr
PE (TTM)
75.7
Industry median 36.1 (152 companies)
Price to Book
30.3
PEG (TTM)
-2.9
Institutions holding %
0.11%
FII + DII, latest filed period
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
Data unavailable.
Free Cash Flow
₹4 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
1600.00%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
0.00%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
115.05%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
112.37%
as of June 30, 2025
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
336.32%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
3.63
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.06
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
38.98
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
19.11%
as of June 30, 2025
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
87.88%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
65.33%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
4.44%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
31.66%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
5.81%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

1 of 6 met
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • Yes Debt to equity is below 0.5 (0.06)
  • No Return on equity is 15% or more (5.8%)
  • No Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

2 of 3 met
  • No FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

2 of 2 met
  • Yes Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

2 of 4 met
  • No Valuation score is Undervalued (70 or more)
  • Yes Momentum score is Bullish (70 or more)
  • Yes Price is above the 5, 10 and 20 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
3.0%
Low 60.7700 · High 63.3600
1W return
9.3%
Low 55.1300 · High 63.3600
1M return
39.9%
Low 44.3400 · High 63.3600
52W return
Data unavailable.
Low 40.0600 · High 63.3600
Lifetime High ₹62.0900 (Sept. 30, 2026)
Lifetime Low ₹41.4200 (Aug. 14, 2026)

Full price history and technicals →

EMA & SMA

Bullish3
Bearish0
5D
59.5
10D
57.8
20D
54.6

Delivery and volume

Day avg. delivery
23.4%
Week avg. delivery
23.4%
Month avg. delivery
33.9%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

62.07
Pivot
First resistance63.38
Second resistance64.66
Third resistance65.97
First support60.79
Second support59.48
Third support58.20
Day RSI78.5
Day MFI77.9
Day MACD—
Day MACD signal—

Beta

1M-2.03
3M-1.68
1Y-1.68
3Y-1.68

Price change analysis

↑ 39.9%
Over 1 Month
LowHigh
44.3463.36
—
Over 3 Months
LowHigh
40.0663.36
—
Over 6 Months
LowHigh
40.0663.36
—
Over 1 Year
LowHigh
40.0663.36
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →

Data unavailable (needs at least 2 historical quarters with both a filed EPS and a matching trading day).

Revenue (June 30, 2026)
₹24 Cr
Net profit (June 30, 2026)
₹— Cr
Basic EPS (June 30, 2026)
₹0.3400

Ranks #71 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter50.96%
  • Public48.93%

Largest holders

Data unavailable.

Historical promoter holding

Promoters holdings were unchanged at 50.96% in Jun 2026 qtr

Historical fii holding

All shareholding details →

Last 12 months ₹0.01 per share
Dividend yield 0.02%
Ex-dateSubjectPer share (₹)Record date
21 Sep 2026 Dividend - Re 0.01 Per Share 0.0100 21 Sep 2026

Corporate Actions

Full history (2 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
—NAME_CHANGEName changed from Relish Pharmaceuticals Ltd. to Shukra Pharmaceuticals Limited

All corporate actions →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
22 Aug 2026 Other business matters —

Corporate Announcements

All 22 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
29 Sep 2026 Shareholders meeting Shukra Pharmaceuticals Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results.
29 Sep 2026 AGM/EGM Shukra Pharmaceuticals Ltd - 524632 - Voting Results And Scrutinizer''s Report
29 Sep 2026 AGM/EGM Shukra Pharmaceuticals Ltd - 524632 - Voting Results With Scrutinizer Report
28 Sep 2026 AGM/EGM Shukra Pharmaceuticals Ltd - 524632 - Shareholder Meeting / Postal Ballot-Outcome of AGM
28 Sep 2026 Outcome of Board Meeting Shukra Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on September 28, 2026.
24 Sep 2026 Trading Window Shukra Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
18 Sep 2026 Record Date Shukra Pharmaceuticals Limited has informed the Exchange that Record date for the purpose of Dividend is 21-Sep-2026.
5 Sep 2026 AGM/EGM Shukra Pharmaceuticals Ltd - 524632 - AGM NOTICE
5 Sep 2026 Others Shukra Pharmaceuticals Ltd - 524632 - Reg. 34 (1) Annual Report.
5 Sep 2026 Shareholders meeting Shukra Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 28, 2026

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.06)
  • Comfortable interest coverage (39.0x)
  • Strong revenue growth YoY (336.3%)

Weaknesses

  • Low Return on Equity (5.8%)

Opportunities

Data unavailable.

Threats

  • PE above 35 (75.7) -- priced for continued strong execution
  • RSI in overbought territory (78.5)

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Shukra Pharmaceuticals Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.